YAP1 signaling and cancer: molecular pathways reveal novel targeting opportunities
Therapeutically inhibiting YAP1/TAZ signaling holds substantial promise. Yet the dual physiological roles of YAP1 in tissue repair and stemness underscore the need for highly selective and temporally controlled interventions. Rational combinations, such as pairing YAP1/TEAD inhibitors with immune checkpoint blockade, anti-fibrotic agents, may enhance clinical benefit. Future work should prioritize the development of robust biomarkers of YAP1 activation, deeper mapping of TEAD-dependent versus TEAD-independent functions, and optimization of strategies that maximize antitumor efficacy while limiting systemic toxicity.
Authors
- Jialin Wu (ORCID: https://orcid.org/0009-0006-6985-3097)
- Ruoxi Tian
- Jiahui Hu (ORCID: https://orcid.org/0000-0003-4352-3250)
- Peiyao Yu
- Yang Lyu (ORCID: https://orcid.org/0000-0001-8579-6332)
- Fuda Xie
- Tiejun Feng
- Bonan Chen
- Wei Kang
- Mingyu Liang
Institutions
- Chinese University of Hong Kong (HK)
- City University of Hong Kong, Shenzhen Research Institute (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Expert Opinion on Therapeutic Targets
- Published
- 2026-03-03
- DOI
- https://doi.org/10.1080/14728222.2026.2638749
- Primary Topic
- Hippo pathway signaling and YAP/TAZ
- Type
- article
- Field-Weighted Citation Impact
- 0.00